Joseph A. Tami

1.7k total citations · 2 hit papers
18 papers, 1.3k citations indexed

About

Joseph A. Tami is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Joseph A. Tami has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Joseph A. Tami's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Cell Adhesion Molecules Research (3 papers). Joseph A. Tami is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Cell Adhesion Molecules Research (3 papers). Joseph A. Tami collaborates with scholars based in United States, Canada and Australia. Joseph A. Tami's co-authors include Richard S. Geary, Joseph L. Witztum, William Shanahan, Sotirios Tsimikas, Rosie Z. Yu, Shuting Xia, Bruce Yacyshyn, Mary Beth Bowen-Yacyshyn, C. Frank Bennett and Lawrence D. Jewell and has published in prestigious journals such as The Lancet, Gastroenterology and European Heart Journal.

In The Last Decade

Joseph A. Tami

18 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

2016 544 citations Nicholas J. Viney, Julian C. van Capelleveen et al. The Lancet profile →
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

2021 146 citations Jean‐Claude Tardif, Ewa Karwatowska‐Prokopczuk et al. European Heart Journal profile →

Peers

Joseph A. Tami

SURGE

CCM

IMMUN

EDM

Hiroaki Shimoyamada Japan

Els Brouwers Belgium

Tamito Sasaki Japan

H. Wurm Austria

Michele Quaranta Italy

Torgun Wæhre Norway

Padmini Malladi United States

Fumin Fu United States

Stacy Carl-McGrath Germany

Samir Saheb France

Hiroaki Shimoyamada Japan

Joseph A. Tami

307 ×0.5

SURGE

426 ×1.1

133 ×0.4

CCM

107 ×0.4

IMMUN

172 ×0.7

EDM

Citations per year, relative to Joseph A. Tami Joseph A. Tami (= 1×) peers Hiroaki Shimoyamada

Countries citing papers authored by Joseph A. Tami

Since Specialization

Citations

This map shows the geographic impact of Joseph A. Tami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph A. Tami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph A. Tami more than expected).

Fields of papers citing papers by Joseph A. Tami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph A. Tami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph A. Tami. The network helps show where Joseph A. Tami may publish in the future.

Co-authorship network of co-authors of Joseph A. Tami

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph A. Tami. A scholar is included among the top collaborators of Joseph A. Tami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph A. Tami. Joseph A. Tami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Prohaska, Thomas A, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.. (2023). APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 17(3). 406–411. 36 indexed citations

Oral, Elif A, Abhimanyu Garg, Joseph A. Tami, et al.. (2022). Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study. Journal of clinical lipidology. 16(6). 833–849. 47 indexed citations

Tardif, Jean‐Claude, Ewa Karwatowska‐Prokopczuk, Christie M. Ballantyne, et al.. (2021). Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal. 43(14). 1401–1412. 146 indexed citations breakdown →

Curtis, Brian R., Lijiang Shen, Eugene Schneider, et al.. (2020). Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. Nucleic Acid Therapeutics. 30(2). 94–103. 26 indexed citations

O’Dea, Louis, Joseph A. Tami, Veronica J. Alexander, et al.. (2020). Efficacy and safety of volanesorsen for the treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study. Endocrine Abstracts. 4 indexed citations

Viney, Nicholas J., Julian C. van Capelleveen, Richard S. Geary, et al.. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 388(10057). 2239–2253. 544 indexed citations breakdown →

Kahan, Barry D., Stanislaw M. Stepkowski, Murat Kılıç, et al.. (2004). Phase I and Phase II Safety and Efficacy Trial of Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302) for the Prevention of Acute Allograft Rejection. Transplantation. 78(6). 858–863. 23 indexed citations

Sewell, K. Lea, Richard S. Geary, Brenda F. Baker, et al.. (2002). Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α. Journal of Pharmacology and Experimental Therapeutics. 303(3). 1334–1343. 99 indexed citations

Maksymowych, Walter P., Warren D. Blackburn, Joseph A. Tami, & William Shanahan. (2002). A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.. PubMed. 29(3). 447–53. 39 indexed citations

10.

Yacyshyn, Bruce, W.Y. Chey, J S Goff, et al.. (2001). A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels. Gastroenterology. 120(5). A279–A280. 7 indexed citations

11.

Yacyshyn, Bruce, Mary Beth Bowen-Yacyshyn, Lawrence D. Jewell, et al.. (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 114(6). 1133–1142. 295 indexed citations

12.

Tami, Joseph A. & Ronald P. Evens. (1996). Evaluation of Biotechnology Products. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(4). 527–536. 3 indexed citations

13.

Raaphorst, Frank M., Joseph A. Tami, & Igñacio Sanz. (1996). Cloning of Size-Selected Human Immunoglobulin Heavy-Chain Rearrangements from Third Complementarity-Determining Region Fingerprint Profiles. BioTechniques. 20(1). 78–87. 14 indexed citations

14.

Yeh, Trai‐Ming, Joseph A. Tami, & Keith A. Krolick. (1992). EXACERBATED MUSCLE DYSFUNCTION BY PROCAINAMIDE IN RATS WITH EXPERIMENTAL MYASTHENIA GRAVIS. Drug and Chemical Toxicology. 15(1). 53–65. 3 indexed citations

15.

Godley, Paul J., et al.. (1990). Procainamide-Induced Myasthenic Crisis. Therapeutic Drug Monitoring. 12(4). 411–414. 10 indexed citations

16.

Tami, Joseph A.. (1987). Immunology for the Clinical Pharmacist. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 7(2). S3–6. 1 indexed citations

17.

Tami, Joseph A., et al.. (1986). Monoclonal antibody technology. American Journal of Health-System Pharmacy. 43(11). 2816–2825. 23 indexed citations

18.

Tami, Joseph A., et al.. (1986). The Immune System. American Journal of Health-System Pharmacy. 43(10). 2483–2494. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact